Hematology Oncology and Stem Cell Therapy Hematology Oncology and Stem Cell Therapy RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Skin involvement in Burkitt’s lymphoma
We report a case of a 9-years old boy with stage 4 Burkitt's lymphoma with skin involvement who tested negative for human immune-deficiency virus. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Beliefs about hydroxyurea in youth with sickle cell disease
ConclusionsBeliefs about hydroxyurea correlated with HRQOL scores and adherence levels. Addressing patients’ concern about hydroxyurea and medications overall as well as routine assessment of adherence and beliefs could help to overcome adherence barriers. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Damocles’ syndrome revisited: Update on the fear of cancer recurrence in the complex world of today’s treatments and survivorship
ConclusionLiterature on the fear of cancer recurrence has begun to emerge. However, herein we provide a unique approach through the use of a metaphor: Cicero’s story of Damocles’ sword. We aim to outline the many fear-related and emotional challenges faced by cancer survivors with an extensive review of studies demonstrating such challenges. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine/busulfan conditioning
ConclusionDose difference of rATG-F did not influence survival parameters; however, increasing the dose to 30 mg/kg seems to be effective for reducing cGVHD with an increase in infection rate requiring close monitoring of infections in AML patients who received myeloablative fludarabine/busulfan conditioning. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience
ConclusionR–MTX–ARA-C followed by autologous stem cell transplantation seems a promising strategy with high response rates in PCNSL. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

End of therapy minimal residual disease (MRD) measurement in children with ALL does not predict relapse
Publication date: March 2018Source: Hematology/Oncology and Stem Cell Therapy, Volume 11, Issue 1Author(s): Tahani Hani Sarrawi, Ismael Zayyat, Fareed Barakat, Maha Rezeq, Salam Abu Jmaian, Faris MadanatAbstractMinimal residual disease (MRD) monitoring opened a new era for childhood acute lymphoblastic leukemia (ALL), and is widely used for risk adapted therapy in the major study groups (Borowitz et al. 2015; Eckert et al., 2015; Peregud-Pogorzelsk et al., 2003). MRD is measured either by polymerase chain reaction (PCR) or flow cytometry (FCM) (Campana, 2009). Most studies have concentrated on measuring MRD during or at en...
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Polycythemia vera masked due to severe iron deficiency anemia
We present a case where there was a delay in the diagnosis of polycythemia because of menorrhagia in the past. On admission, the patient presented with elevated red and white blood cell counts, erythropoietin was low, and polycythemia was then suspected. A bcr-abl test was performed to rule out chronic myelogenous leukemia. JAK2 mutation was positive, and the patient was diagnosed with polycythemia vera. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Severe Plasmodium vivax cerebral malaria complicated by hemophagocytic lymphohistiocytosis treated with artesunate and doxycycline
Publication date: March 2018Source: Hematology/Oncology and Stem Cell Therapy, Volume 11, Issue 1Author(s): Sawsan Amireh, Hamid Shaaban, Gunwant GuronAbstractMalaria-related hemophagocytic lymphohistiocytosis is a rare, potentially fatal, hyperinflammatory disease entity which can be challenging to diagnose and treat. It is usually associated with Plasmodium falciparum infection. It is less frequently associated with Plasmodium vivax. Here we report an unusual case of a 23-year-old healthy Nigerian man who presented with fever, microangiopathic hemolytic anemia, acute renal failure, and confusion, and was diagnosed as hav...
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer
ConclusionThe combination of neoadjuvant chemotherapy with wP + wCb before anthracycline chemotherapy can be tolerated by patients with triple-negative breast cancer. Complete pathologic response rates were comparable with those historically seen. Careful selection of patients is fundamental as this regimen is associated with a high incidence of hematologic toxicity. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Impact of vitamin D deficiency on increased blood eosinophil counts
ConclusionVitamin D deficiency was associated with higher blood eosinophil count. These results support the possible role of vitamin D in the eosinophil immune response. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies
Publication date: March 2018Source: Hematology/Oncology and Stem Cell Therapy, Volume 11, Issue 1Author(s): Hind Rafei, Mohamed A. Kharfan-DabajaAbstractMore effective therapies are emerging, with better toxicity profiles, and are being incorporated into modern treatment algorithms of chronic lymphocytic leukemia at various stages of the disease, including for patients harboring Del17p and/or aberrant TP53. Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, has demonstrated impressive response rates in the relapsed/refractory setting, including in the setting of Del17p and/or TP53 mutations. Venetoclax, an inhibitor of...
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Hematological parameters and red blood cell morphological abnormality of Glucose-6-Phosphate dehydrogenase deficiency co-inherited with thalassemia
ConclusionG-6-PD deficiency co-inherited with thalassemia in males was present in 10% of the participants, resulting in worsening of red blood cell pathology compared with inheritance of thalassemia alone. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Low, fixed dose defibrotide in management of hepatic veno-occlusive disease post stem cell transplantation
ConclusionLow fixed dose defibrotide initiated early seems to be effective and safe in treatment of VOD. This is relevant in a resource limited setting and warrants prospective evaluation. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Successful treatment of pure red cell aplasia with high-dose dexamethasone after ABO-incompatible allogeneic hematopoietic stem cell transplantation
Publication date: March 2018Source: Hematology/Oncology and Stem Cell Therapy, Volume 11, Issue 1Author(s): Rosario Varela Gómez, Goretti Vázquez Vázquez, Victor Noriega Concepción, Andrea Galego García, Concepción Andón SaavedraAbstractThe literature reports an incidence of Pure Red Cell Aplasia (PRCA) ranging from 6-30% of all cases of ABO-incompatible HSCT. Although most patients resolve spontaneously after withdrawal immunosuppression, some of them require more aggressive treatment to manage this condition. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?
Publication date: Available online 16 March 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Erden Atilla, Ugur Sahin, Pinar Ataca Atilla, Mustafa Merter, Elif Ozyurek, Koray Ceyhan, Sinem Civriz BozdagAbstractPrimary central nervous system lymphoma (PCNSL), has an aggressive course and in untreated patients median survival is limited to three months. For relapsed PCNSL, the treatment options are few and results are usually unsatisfactory. Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) has been widely used for treatment of relapsed/refractory NHL patients. However there are limited data whethe...
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research